Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples